- Home
- PRAX vs UDMY Comparison
PRAX vs UDMY Comparison
Compare PRAX & UDMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- UDMY
- Stock Information
- Founded
- PRAX 2015
- UDMY 2009
- Country
- PRAX United States
- UDMY United States
- Employees
- PRAX N/A
- UDMY N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- UDMY Other Consumer Services
- Sector
- PRAX Health Care
- UDMY Real Estate
- Exchange
- PRAX Nasdaq
- UDMY Nasdaq
- Market Cap
- PRAX 952.1M
- UDMY 1.1B
- IPO Year
- PRAX 2020
- UDMY 2021
- Fundamental
- Price
- PRAX $52.00
- UDMY $6.45
- Analyst Decision
- PRAX Strong Buy
- UDMY Buy
- Analyst Count
- PRAX 10
- UDMY 10
- Target Price
- PRAX $93.30
- UDMY $9.89
- AVG Volume (30 Days)
- PRAX 435.3K
- UDMY 1.8M
- Earning Date
- PRAX 11-05-2025
- UDMY 10-28-2025
- Dividend Yield
- PRAX N/A
- UDMY N/A
- EPS Growth
- PRAX N/A
- UDMY N/A
- EPS
- PRAX N/A
- UDMY N/A
- Revenue
- PRAX $7,765,000.00
- UDMY $795,538,000.00
- Revenue This Year
- PRAX N/A
- UDMY $2.58
- Revenue Next Year
- PRAX $20.00
- UDMY $4.19
- P/E Ratio
- PRAX N/A
- UDMY N/A
- Revenue Growth
- PRAX 338.45
- UDMY 3.93
- 52 Week Low
- PRAX $26.70
- UDMY $5.68
- 52 Week High
- PRAX $91.83
- UDMY $10.61
- Technical
- Relative Strength Index (RSI)
- PRAX 56.68
- UDMY 34.92
- Support Level
- PRAX $46.99
- UDMY $6.88
- Resistance Level
- PRAX $55.86
- UDMY $6.98
- Average True Range (ATR)
- PRAX 3.62
- UDMY 0.24
- MACD
- PRAX 0.56
- UDMY -0.06
- Stochastic Oscillator
- PRAX 74.41
- UDMY 1.74
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About UDMY Udemy Inc.
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.